Header Logo

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Usmani, Saad
Item TypeName
Concept Multiple Myeloma
Academic Article Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis.
Academic Article Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma.
Academic Article Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement.
Academic Article International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
Academic Article Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival.
Academic Article Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
Academic Article Multiple myeloma: is it time for biomarker-driven therapy?
Academic Article Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.
Academic Article Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.
Academic Article Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ?3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD.
Academic Article The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy.
Academic Article Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group.
Academic Article Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups.
Academic Article Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project.
Academic Article CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.
Academic Article Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma.
Academic Article Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma.
Academic Article Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.
Academic Article Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
Academic Article Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.
Academic Article Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma.
Academic Article A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
Academic Article Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease.
Academic Article Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Academic Article Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma.
Academic Article Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple Myeloma.
Academic Article Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.
Academic Article Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Academic Article Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.
Academic Article Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data.
Academic Article NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.
Academic Article Thalidomide and its analogues in the treatment of Multiple Myeloma.
Academic Article Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3.
Academic Article Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
Academic Article Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma.
Academic Article Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma.
Academic Article How long can we let the myeloma smolder?
Academic Article The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1.
Academic Article Molecular chaperone gp96 is a novel therapeutic target of multiple myeloma.
Academic Article Analysis of CD34+ cell collection using two mobilization regimens for newly diagnosed multiple myeloma patients reveals the separate impact of mobilization and collection variables.
Academic Article Patterns of central nervous system involvement in relapsed and refractory multiple myeloma.
Academic Article Novel drug combinations for the management of relapsed/refractory multiple myeloma.
Academic Article Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols.
Academic Article HSP90 inhibitors as therapy for multiple myeloma.
Academic Article Rituximab and intravenous immunoglobulin (IVIG) for the management of acquired factor VIII inhibitor in multiple myeloma: case report and review of literature.
Academic Article American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.
Academic Article Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging.
Academic Article Cutaneous manifestations of multiple myeloma and other plasma cell proliferative disorders.
Academic Article Maintenance lenalidomide after transplantation: How much is enough?
Academic Article Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
Academic Article Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.
Academic Article International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
Academic Article Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.
Academic Article Melphalan continues to rock the myeloma world.
Academic Article Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison.
Academic Article High-dose chemotherapy and autologous stem cell transplantation for multiple myeloma in HIV-positive patients in the highly active antiretroviral therapy era: the myeloma institute of research and therapy experience.
Academic Article Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
Academic Article Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).
Academic Article Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma.
Academic Article High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.
Academic Article Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma.
Academic Article Treatment approach for young, fit, newly diagnosed multiple myeloma patients.
Academic Article Mortality by a proxy performance status as defined by a claims-based measure for disability status in older patients with newly diagnosed multiple myeloma in the United States.
Academic Article A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Academic Article INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma.
Academic Article Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses.
Academic Article Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
Academic Article Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma.
Academic Article Practical Considerations in Managing Relapsed Multiple Myeloma.
Academic Article Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.
Academic Article BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee.
Academic Article Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.
Academic Article Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Academic Article Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.
Academic Article International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.
Academic Article Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies.
Academic Article Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.
Academic Article Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Academic Article Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.
Academic Article Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.
Academic Article Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.
Academic Article Extramedullary multiple myeloma.
Academic Article Quadruplets come of age for newly diagnosed multiple myeloma.
Academic Article Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Academic Article Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.
Academic Article Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses.
Academic Article Extramedullary Disease in Multiple Myeloma.
Academic Article Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
Academic Article Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO).
Academic Article Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab.
Academic Article Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.
Academic Article Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma.
Academic Article Management of newly diagnosed transplant ineligible multiple myeloma.
Academic Article An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma.
Academic Article Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
Academic Article Subcutaneous versus intravenous daratumumab in multiple myeloma - Authors' reply.
Academic Article Daratumumab subcutaneous formulation for the treatment of multiple myeloma.
Academic Article International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.
Academic Article Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: Efficacy in transplant-ineligible untreated myeloma.
Academic Article Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results.
Academic Article Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.
Academic Article Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis.
Academic Article Chimeric Antigen Receptor T-cell Therapy for Multiple Myeloma.
Academic Article International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM).
Academic Article Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients.
Academic Article Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma.
Academic Article Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX.
Academic Article Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression.
Academic Article Defining and Managing High-Risk Multiple Myeloma: Current Concepts.
Academic Article Thromboembolism Incidence and Risk Factors in Multiple Myeloma After First Exposure to Immunomodulatory Drug-Based Regimens.
Academic Article Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial.
Academic Article Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.
Academic Article Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life.
Academic Article Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical Practice.
Academic Article Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR.
Academic Article Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study.
Academic Article Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.
Academic Article Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.
Academic Article Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report.
Academic Article Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
Academic Article How to Treat High-Risk Myeloma at Diagnosis and Relapse.
Academic Article CAR T-cell therapy for multiple myeloma: state of the art and prospects.
Academic Article Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy.
Academic Article Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
Academic Article The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.
Academic Article Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Academic Article Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
Academic Article Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Academic Article Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
Academic Article Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study.
Academic Article Cross fire: Daratumumab-based therapies are standard of care in newly diagnosed multiple myeloma.
Academic Article Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma.
Academic Article Teclistamab, a B-cell maturation antigen?×?CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Academic Article Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma.
Academic Article A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly.
Academic Article Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis.
Academic Article Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
Academic Article Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation.
Academic Article Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.
Academic Article Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies.
Academic Article Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma.
Academic Article Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage.
Academic Article Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
Academic Article Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.
Academic Article Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA.
Concept Smoldering Multiple Myeloma
Academic Article Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.
Academic Article Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment.
Academic Article Current approaches to management of newly diagnosed multiple myeloma.
Academic Article Extramedullary disease in multiple myeloma: a systematic literature review.
Academic Article ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma.
Academic Article Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.
Academic Article BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy.
Academic Article Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma.
Academic Article Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience.
Academic Article Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study.
Academic Article Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma.
Academic Article Perspectives on the Risk-Stratified Treatment of Multiple Myeloma.
Academic Article Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
Academic Article Teclistamab in Relapsed or Refractory Multiple Myeloma.
Academic Article Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma.
Academic Article Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Academic Article Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial.
Academic Article Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma.
Academic Article Ex vivo efficacy of BCMA-bispecific antibody TNB-383B in relapsed/refractory multiple myeloma.
Search Criteria
  • Multiple Myeloma